Profusa shares surge 24.6% premarket after securing purchase orders for Lumee Tissue Oxygen Monitoring and raising 2026 revenue guidance.

Profusa Inc. (PFSA) surged 24.60% in premarket trading following the announcement that it received purchase orders for its Lumee™ Tissue Oxygen Monitoring system and raised its 2026 revenue guidance. The news, reported six days prior, highlights growing commercial adoption of the company’s oxygen monitoring technology and reinforces its path toward achieving $250 million in revenue by 2030. This update, coupled with recent collaborations with Mayo Clinic and expanded European distribution partnerships, signals strong demand for Profusa’s products and operational progress. The upward revision in revenue expectations directly supports investor optimism, aligning with the stock’s sharp premarket gain.